Licensing plasma master files and vaccine antigen master files

AI Summary

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued guidance regarding the licensing of Plasma Master Files (PMFs) and Vaccine Antigen Master Files (VAMFs) in the United Kingdom. As this is a general regulatory document rather than an inspection report, it does not list a specific company, inspection dates, or violations; instead, it establishes the mandatory framework for all participating entities. The MHRA continues to recognize existing European Union PMFs and their associated inspections for the time being but requires national applications for new submissions. Under this framework, PMF holders must notify the MHRA of the outcomes of annual updates and any European Medicines Agency (EMA) determinations within four weeks of completion. For VAMFs, no formal UK procedure currently exists, and applicants must contact the agency directly for guidance. Required actions for compliance include strict adherence to these notification windows via the designated PMF mailbox. The MHRA maintains the authority to request further information if specific UK public health issues are identified. This guidance ensures that the MHRA retains oversight of biological materials while maintaining temporary continuity with established European standards.